These findings well fit with the in vivo demonstration that administration of RG7155, a monoclonal antibody that inhibits MCSF-1R activation, to CRC patients led to striking reductions of CSF-1R+CD163+ macrophages in tumor tissues (45). This evidence concerns the gene CD163 and neoplasm.